Skip to main content

Table 1 Trials design data

From: Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov

  Number Percent
Trial Phase
 Phase 2 188 87.0
 Phase 2/Phase 3 3 1.4
 Phase 3 25 11.6
Number of Arms
 1 107 49.5
 2 83 38.4
 ≥3 13 9.7
 NR 5 2.3
Sample Size
 0 to 50 90 41.7
 51 to 100 62 28.7
 101 to 200 36 16.7
 201 to 300 11 5.1
 301 or more 16 7.4
 NR 1 0.5
Interventional Model
 Single Group Assignment 116 53.7
 Parallel Assignment 92 42.6
 Factorial Assignment 1 0.5
 Crossover Assignment 2 0.9
 NR 5 2.3
Treatment Allocation
 Non-Randomized 47 21.8
 Randomized 86 39.8
 NR 83 38.4
Masking (Blinding)
 Open Label 187 86.6
 Single Blind 2 0.9
 Double Blind 25 11.6
 NR 2 0.9
Endpoint Classification
 Safety/Efficacy Study 109 50.5
 Efficacy Study 75 34.7
 Safety Study 4 1.9
 Bio-equivalence Study 1 0.5
 Pharmacodynamics Study 1 0.5
 Pharmacokinetics Study 1 0.5
 NR 25 11.6
Primary Purpose of Trial
 Treatment 207 95.8
 Diagnostic 3 1.4
 Health Services Research 1 0.5
 Basic Science 2 0.9
 Supportive Care 1 0.5
 NR 2 0.9